English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

To investigate the expression of EPLIN-α, epithelial protein lost in neoplasm, in human breast cancer tissues/cells and investigate the cellular impact of EPLIN-α on breast cancer cells.    Experimental design  EPLIN- α  was determined in tumour (n = 120) and normal mammary tissues (n = 32), and cancer cell lines (n = 16). Cell invasion,  in vitro  and  in vivo  growth of cells transfected with EPLIN- α  were evaluated using  in vitro  invasion assay,  in vitro  and  in vivo  tumour model. Cellular migration was analysed using Electric Cell Impedance Sensing assays.    Results  Low level of EPLIN- α  was seen in tumour tissues. Grade-2/3 tumours had significantly lower levels of EPLIN- α  compared with grade-1 (p = 0.047 and p = 0.046 vs grade-1, respectively). Patients with poor prognosis had a significantly lower levels of EPLIN- α  compared with those with good prognosis (p = 0.0081). Patients who developed recurrence and died of breast cancer had significantly lower levels of EPLIN- α  compared with those who remained disease free (p = 0.0003 and p = 0.0008, respectively) (median follow-up 10 years). Patients with high levels of EPLIN- α  transcript had a longer survival than those with low levels. Over-expression of EPLIN- α  in breast cancer cells by way of transfection rendered cells less invasive, less motile and growing at a slower pace  in vitro  and  in vivo . An ERK inhibitor was shown to be able to abolish the effect of EPLIN expression.    Conclusion  It is concluded that expression of EPLIN- α  in breast cancer is down-regulated in breast cancer cells and tissues, a change linked to the prognosis. EPLIN- α  acts as a potential tumour suppressor by inhibition of growth and migration of cancer cells.

Eplin-alpha expression in human breast cancer, the impact on cellular migration and clinical outcome